Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection.

Groeneveld, Geert H; Marbus, Sierk D; Ismail, Noor; de Vries, Jutte J C; Schneeberger, Peter; Oosterheert, Jan Jelrik; van Dissel, Jaap T; de Boer, Mark G J

Groeneveld, Geert H; Marbus, Sierk D; Ismail, Noor; de Vries, Jutte J C; Schneeberger, Peter; Oosterheert, Jan Jelrik; van Dissel, Jaap T; de Boer, Mark G J.

Afiliação

Groeneveld GH; Department of Infectious Diseases and Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands. Electronic address: g.h.groeneveld@lumc.nl.
Marbus SD; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM), Bilthoven, The Netherlands.
Ismail N; Department of Infectious Diseases and Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands.
de Vries JJC; Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands.
Schneeberger P; Department of Medical Microbiology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
Oosterheert JJ; Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Utrecht, The Netherlands.
van Dissel JT; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM), Bilthoven, The Netherlands; Department of Infectious Diseases and Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands.
de Boer MGJ; Department of Infectious Diseases and Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands.

Int J Antimicrob Agents ; 56(5): 106155, 2020 Nov.

Article em En | MEDLINE | ID: mdl-32898685

Assuntos

Antivirais/uso terapêutico; Influenza Humana/tratamento farmacológico; Oseltamivir/uso terapêutico; Idoso; Comorbidade; Feminino; Mortalidade Hospitalar/tendências; Humanos; Influenza Humana/complicações; Influenza Humana/mortalidade; Tempo de Internação; Masculino; Pessoa de Meia-Idade; Países Baixos; Neuraminidase/antagonistas & inibidores; Pontuação de Propensão; Estudos Retrospectivos; Resultado do Tratamento

Palavras-chave

Complications; Influenza; Mortality; Oseltamivir; Treatment

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 1_doencas_nao_transmissiveis / 1_doencas_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles / 6_other_respiratory_diseases Assunto principal: Antivirais / Influenza Humana / Oseltamivir Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Int J Antimicrob Agents Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google